Published in J Negat Results Biomed on November 17, 2004
Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A (2008) 2.30
Targeting wild-type and mutant p53 with small molecule CP-31398 blocks the growth of rhabdomyosarcoma by inducing reactive oxygen species-dependent apoptosis. Cancer Res (2010) 0.98
Pharmacological activation of p53 in cancer cells. Curr Pharm Des (2011) 0.92
Targeting Oncogenic Mutant p53 for Cancer Therapy. Front Oncol (2015) 0.83
Targeted therapies in the management of metastatic bladder cancer. Biologics (2007) 0.79
Characterization of the new human pleomorphic undifferentiated sarcoma TP53-null cell line mfh-val2. Cytotechnology (2017) 0.75
WAF1, a potential mediator of p53 tumor suppression. Cell (1993) 38.72
Surfing the p53 network. Nature (2000) 35.36
p53 mutations in human cancers. Science (1991) 31.96
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell (1990) 20.60
GAL4-VP16 is an unusually potent transcriptional activator. Nature (1988) 16.53
Studies on the transformation of intact yeast cells by the LiAc/SS-DNA/PEG procedure. Yeast (1995) 13.20
p53: puzzle and paradigm. Genes Dev (1996) 13.16
A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol (1999) 5.67
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med (2002) 5.18
Pharmacological rescue of mutant p53 conformation and function. Science (1999) 3.91
Transcriptional regulation by p53 through intrinsic DNA/chromatin binding and site-directed cofactor recruitment. Mol Cell (2001) 3.74
Latent and active p53 are identical in conformation. Nat Struct Biol (2001) 3.47
Small peptides activate the latent sequence-specific DNA binding function of p53. Cell (1995) 2.96
Differential activation of CREB by Ca2+/calmodulin-dependent protein kinases type II and type IV involves phosphorylation of a site that negatively regulates activity. Genes Dev (1994) 2.95
Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc Natl Acad Sci U S A (2001) 2.92
Contact with a component of the polymerase II holoenzyme suffices for gene activation. Cell (1995) 2.85
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene (2000) 2.65
Allosteric activation of latent p53 tetramers. Curr Biol (1994) 2.25
Mammalian p53 can function as a transcription factor in yeast. Nucleic Acids Res (1992) 2.07
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat Med (1997) 1.68
A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci U S A (2002) 1.58
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene (2002) 1.51
Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol Cell Biol (1999) 1.30
Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. Mol Cell Biol (2003) 1.25
Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem (2002) 1.25
The p53 stabilizing compound CP-31398 induces apoptosis by activating the intrinsic Bax/mitochondrial/caspase-9 pathway. Exp Cell Res (2002) 1.08
Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments. Oncogene (1999) 0.91
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature (2010) 4.85
Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol (2010) 2.10
DNA looping induced by a transcriptional enhancer in vivo. Nucleic Acids Res (2005) 1.32
Direct in vivo screening of intrabody libraries constructed on a highly stable single-chain framework. J Biol Chem (2002) 1.25
Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations. J Med Chem (2005) 1.05
In silico discovery of beta-secretase inhibitors. J Am Chem Soc (2006) 1.01
Organ polarity in Arabidopsis. NOZZLE physically interacts with members of the YABBY family. Plant Physiol (2004) 0.97
Antigen-independent selection of intracellular stable antibody frameworks. Methods (2004) 0.94
Cell growth selection system to detect extracellular and transmembrane protein interactions. Biochim Biophys Acta (2003) 0.86
Novel yeast cell-based assay to screen for inhibitors of human cytomegalovirus protease in a high-throughput format. Antimicrob Agents Chemother (2006) 0.84
Coupling homologous recombination with growth selection in yeast: a tool for construction of random DNA sequence libraries. Biotechniques (2004) 0.82
Yeast growth selection system for detecting activity and inhibition of dimerization-dependent receptor tyrosine kinase. Biotechniques (2005) 0.80
Quenching accumulation of toxic galactose-1-phosphate as a system to select disruption of protein-protein interactions in vivo. Biotechniques (2004) 0.78
Inhibition of keratinocyte proliferation by phospholipid-conjugates of a TLR7 ligand in a Myc-induced hyperplastic actinic keratosis model in the absence of systemic side effects. Eur J Dermatol (2013) 0.77
Human beta-secretase activity in yeast detected by a novel cellular growth selection system. Biochim Biophys Acta (2003) 0.77
Yeast growth selection system for the identification of cell-active inhibitors of beta-secretase. Biochim Biophys Acta (2004) 0.76
Searching for the most effective screening system to identify cell-active inhibitors of beta-secretase. Biol Chem (2004) 0.76
The CUP1 upstream repeated element renders CUP1 promoter activation insensitive to mutations in the RNA polymerase II transcription complex. Nucleic Acids Res (2002) 0.75
Monocyte targeting and activation by cationic liposomes formulated with a TLR7 agonist. Expert Opin Drug Deliv (2015) 0.75